Driven by several novel regimens recently receiving approval in the US and in Europe, high cure rates exceeding 90% are now achievable for most patients suffering from chronic hepatitis C. As a result of this unprecedented success, the industry is reaching a new phase in the fight against this deadly infectious disease. The pressure is now shifting to the healthcare providers to determine if the future of hepatitis C treatment will include a (near) eradication in the developed world, or if hepatitis C will remain a debilitating and life-threatening factor in our society.
Hovione and Vertex Pharma have teamed up to set up a continuous manufacturing facility at the former’s site in New Jersey, US.
Recent reports have shown that Gilead's ($GILD) hep C superstars, Sovaldi and Harvoni, are linked to fewer serious side effects than AbbVie's ($ABBV) rival med Viekira Pak. But Harvoni could take home the prize of being the safest option of the three drugs.
Vertex Pharmaceuticals Inc. has ranked high on investors’ lists of likely biotech acquisition targets. Now that the drugmaker is on the path to profit, it’s the one ready to go shopping.
Mid-cap biotech beats most of the big dogs with 21.9% revenue growth
Another One Bites The Dust: Merck Cans Hep C Fighter Victrelis as New Meds Take Flight
High Prices for Cancer Drugs are set at Launch: